Pulmonary manifestations of antiphospholipid syndrome: a retrospective analysis of 67 patients
| Autor: | Sevinc Sarinc Ulasli, Ali Akdogan, Şule Apraş Bilgen, Oguz Karcioglu, Elif Babaoglu, Deniz Koksal, Berkan Armagan, Alper Sari |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Adult
Male medicine.medical_specialty Hypertension Pulmonary Hemorrhage 030204 cardiovascular system & hematology Gastroenterology 03 medical and health sciences 0302 clinical medicine Antiphospholipid syndrome Internal medicine medicine Retrospective analysis Humans In patient 030212 general & internal medicine Retrospective Studies Lupus anticoagulant Hematology business.industry Mean age Diffuse alveolar hemorrhage Middle Aged medicine.disease Antiphospholipid Syndrome Rheumatology Venous thrombosis Lupus Coagulation Inhibitor Antibodies Antiphospholipid Chronic thromboembolic pulmonary hypertension Female Cardiology and Cardiovascular Medicine business |
| Zdroj: | Journal of thrombosis and thrombolysis. 52(2) |
| ISSN: | 1573-742X |
| Popis: | Background: Antiphospholipid syndrome (APS) is a systemic autoimmune disorder characterized by arterial and/or venous thrombosis accompanied by persistently elevated levels of antiphospholipid antibodies. We aimed to evaluate pulmonary manifestations of APS. Method: We retrospectively reviewed the data of patients who were followed in the department of rheumatology with the diagnosis of APS between October 2010 and May 2017. Demographic data, clinical, radiological and laboratory findings were recorded. Results: The study included 67 patients (56 female/11 male) with a mean age of 39±13 years. Pulmonary manifestations such as parenchymal and/or vascular involvement were seen in 12 (17.9%) patients. There were no significant differences between patients with and without pulmonary manifestations in terms of age (p=0.46), comorbidities (p=0.48) and APS duration (p=0.661). Acute pulmonary thromboembolism (PE) was determined in 11 (16.4%), alveolar hemorrhage in 2 (3%) patients. Four patients with acute PE (36%) developed chronic thromboembolic pulmonary hypertension (CTEPH). One patient developed both CTEPH and diffuse alveolar hemorrhage after acute PE during follow up. Antiphosholipid antibody IgM was highly positive in patients with PE compared to patients without PE (p=0.005). Other antiphosholipid antibodies and lupus anticoagulant were not significantly different in patients with and without PE. None of the patients were deceased due to pulmonary manifestations of APS. Conclusion: PE was the most common pulmonary manifestation of APS. The development of CTEPH was high among APS patients. Patients with APS should be closely followed for the onset of PE and CTEPH. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink